Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Wells Fargo analyst Benjamin Burnett maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight and lowers the price...
Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results for the ...
Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.41) per share which missed the analyst consensus estima...
Stephens & Co. analyst Sudan Loganathan initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight r...
Guggenheim analyst Debjit Chattopadhyay reiterates Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and maintains $28 price...
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.
Wells Fargo analyst Benjamin Burnett initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight rating a...
